BRIGHTSTAR: A Pilot Trial of Local Consolidative Therapy (LCT) With Brigatinib in Tyrosine Kinase Inhibitor-Naive ALK-Rearranged Advanced NSCLC
Phase of Trial: Phase 0
Latest Information Update: 21 Aug 2019
Price : $35 *
At a glance
- Drugs Brigatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Acronyms BRIGHTSTAR
- 16 Aug 2019 Planned number of patients changed from 24 to 35.
- 16 Aug 2019 Planned End Date changed from 28 Jan 2023 to 28 Jan 2024.
- 18 Dec 2018 Status changed from not yet recruiting to recruiting.